相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
Manfredi Rizzo et al.
ANGIOLOGY (2010)
Fibrates: no ACCORD on their use in the treatment of dyslipidaemia
Anthony S. Wierzbicki
CURRENT OPINION IN LIPIDOLOGY (2010)
OBESITY New life for antidiabetic drugs
Riekelt H. Houtkooper et al.
NATURE (2010)
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5
Jang Hyun Choi et al.
NATURE (2010)
PPARs and the Cardiovascular System
Milton Hamblin et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
Jean-Charles Fruchart
ATHEROSCLEROSIS (2009)
PPARγ and its ligands: therapeutic implications in cardiovascular disease
Luis Villacorta et al.
CLINICAL SCIENCE (2009)
Anti-Inflammatory Effects of Fibrates: An Overview
Konstantinos Tziomalos et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Direct antiatherosclerotic effects of PPAR agonists
Karin A. M. Jandeleit-Dahm et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Risk of Fractures with Glitazones A Critical Review of the Evidence to Date
Michael Bodmer et al.
DRUG SAFETY (2009)
How safe is the use of thiazolidinediones in clinical practice?
C. V. Rizos et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Atherosclerotic plaque development
Quang T. Bui et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Kushwin Rajamani et al.
LANCET (2009)
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and diseased
Emma Robinson et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Thiazolidinediones: effects on insulin resistance and the cardiovascular
C. E. Quinn et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Nuclear receptors and inflammatory diseases
Kun Wang et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2008)
Pleiotropic effects of thiazolidinediones
C. V. Rizos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
Dipak Panigrahy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The importance of treating multiple cardiometabolic in patients with Type 2 diabetes
Dimitri P. Mikhailidis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
A. C. Keech et al.
LANCET (2007)
Glitazones in the treatment of cardiovascular risk factors
Mohamed Amine Bouhlel et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
PPARα in atherosclerosis and inflammation
Fokko Zandbergen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
M. Amine Bouhlel et al.
CELL METABOLISM (2007)
PPARs and molecular mechanisms of transrepression
Mercedes Ricote et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Justin I. Odegaard et al.
NATURE (2007)
PPARγ-dependent regulation of human macrophages in phagocytosis of apoptotic cells
Gyongyike Majai et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
Jaetaek Kim et al.
EXPERIMENTAL EYE RESEARCH (2007)
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
Philippe Gervois et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ
Serena Ghisletti et al.
MOLECULAR CELL (2007)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications
Rhian M. Touyz et al.
VASCULAR PHARMACOLOGY (2006)
Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque - Effects of rosiglitazone treatment
Raffaele Marfella et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Pathology of the vulnerable plaque
R Virmani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients -: Data from a randomized placebo-controlled trial
F Meisner et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation
AC Calkin et al.
DIABETOLOGIA (2006)
The vascular biology of peroxisorne proliferator-activated receptors: Modulation of atherosclerosis
Subodh Verma et al.
CANADIAN JOURNAL OF CARDIOLOGY (2006)
The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy
Jennifer L. Wilkinson-Berka et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Peroxisome proliferator-activated receptor α controls cellular cholesterol trafficking in macrophages
G Chinetti-Gbaguidi et al.
JOURNAL OF LIPID RESEARCH (2005)
Pioglitazone reduces neointima volume after coronary stent implantation -: A randomized, placebo-controlled, double-blind trial in nondiabetic patients
N Marx et al.
CIRCULATION (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
G Pascual et al.
NATURE (2005)
Therapeutic roles of peroxisome proliferator-activated receptor agonists
B Staels et al.
DIABETES (2005)
Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice
VR Babaev et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus -: Results from a controlled randomized study
MR Langenfeld et al.
CIRCULATION (2005)
Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes
AH Xiang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A dominant negative human peroxisome proliferator-activated receptor (PPAR)α is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms
RK Semple et al.
ENDOCRINOLOGY (2005)
New targets for PPARγ in the vessel wall:: implications for restenosis
D Bruemmer et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells
K Goya et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Clinical interest of PPARs ligands -: Particular benefit in type 2 diabetes and metabolic syndrome
B Vergès
DIABETES & METABOLISM (2004)
Peroxisome proliferator-activated receptor γ:: Implications for cardiovascular disease
WA Hsueh et al.
HYPERTENSION (2004)
The hinge-helix 1 region of peroxisome proliferator-activated receptor γ1 (PPARγ1) mediates interaction with extracellular signal-regulated kinase 5 and PPARγ1 transcriptional activation:: Involvement in flow-induced PPARγ activation in endothelial cells
M Akaike et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Peroxisome proliferator-activated receptor α induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-α activation properties
E Teissier et al.
CIRCULATION RESEARCH (2004)
Peroxisome proliferator-activated receptor-γ calls for activation in moderation:: Lessons from genetics and pharmacology
C Knouff et al.
ENDOCRINE REVIEWS (2004)
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes
D Choi et al.
DIABETES CARE (2004)
Coronary vasomotor abnormalities in insulin-resistant individuals
MJ Quiñones et al.
ANNALS OF INTERNAL MEDICINE (2004)
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus
JS Sidhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: An intravascular ultrasound scanning study
T Takagi et al.
AMERICAN HEART JOURNAL (2003)
PPARα and PPARγ activators suppress the monocyte-macrophage apoB-48 receptor
G Haraguchi et al.
JOURNAL OF LIPID RESEARCH (2003)
Insulin resistance and cardiovascular events with low HDL cholesterol - The Veterans Affairs HDL Intervention Trial (VA-HIT)
SJ Robins et al.
DIABETES CARE (2003)
PPAR agonists in the treatment of atherosclerosis
GA Francis et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an anti inflammatory role for lipoprotein lipase
O Ziouzenkova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial
AE Caballero et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome
G Paradisi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Macrophages, inflammation, and atherosclerosis
MF Linton et al.
INTERNATIONAL JOURNAL OF OBESITY (2003)
Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells
DS Calnek et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice
H Duez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
HB Rubins et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
DA Playford et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
The role of PPARs in atherosclerosis
C Duval et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
H Vosper et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux
TE Akiyama et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease
DM Flavell et al.
CIRCULATION (2002)
Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages
FG Gbaguidi et al.
FEBS LETTERS (2002)
Peroxisome proliferator-activated receptor γ inhibits transforming growth factor β-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3
MG Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor α -: A potential role in the cardiac metabolic stress response
PM Barger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes
A Sugawara et al.
HYPERTENSION RESEARCH (2001)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
G Chinetti et al.
NATURE MEDICINE (2001)
Docosahexaenoic acid, a peroxisome proliferator-activated receptor-α ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase
QN Diep et al.
HYPERTENSION (2000)
Peroxisome proliferator-activate inhibit development of atherosclerosis in LDL receptor-deficient mice
AC Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene
M Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
N Marx et al.
JOURNAL OF IMMUNOLOGY (2000)
Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
M Evans et al.
CIRCULATION (2000)
Expression and function of PPARγ in rat and human vascular smooth muscle cells
RE Law et al.
CIRCULATION (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators
V Pasceri et al.
CIRCULATION (2000)
Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ
JH Han et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
H Shu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
分享论文
